Why Trump’s ‘Cure’ Isn’t Ready for Approval

Shortly after President Trump touted Regeneron Pharmaceuticals’ experimental antibody cocktail treatment for COVID-19 as a “cure,” both Regeneron and Eli Lilly and Company applied to the U.S. government to open their antibody treatments to the public.

The two companies’ drugs work similarly. Neither company has finished its clinical trials yet, but both argue that the pandemic is so urgent that the treatments should be made available immediately.

Regeneron’s treatment, REGN-COV2,…

Read Entire Article Here…

Leave a Reply

Your email address will not be published. Required fields are marked *